Do analysts rate ORMP or SLN?

Silence Therapeutics has a consensus target price of $53.50, indicating a potential upside of 261.73%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Does the media prefer ORMP or SLN?

In the previous week, Oramed Pharmaceuticals had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 2 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.70 beat Oramed Pharmaceuticals' score of 0.01 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Silence Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ORMP or NGNE?

Neurogene has a consensus target price of $83.67, suggesting a potential upside of 122.46%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Neurogene 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Is ORMP or NGNE more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.17% -4.54% Neurogene N/A -45.10% -41.00%

Does the media favor ORMP or NGNE?

In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 4 mentions for Neurogene. Neurogene's average media sentiment score of 1.48 beat Oramed Pharmaceuticals' score of 0.01 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate STTK or ORMP?

Shattuck Labs presently has a consensus price target of $12.78, indicating a potential upside of 83.59%. Given Shattuck Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe Shattuck Labs is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shattuck Labs 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is STTK or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Oramed Pharmaceuticals N/A -5.17% -4.54%

Does the media refer more to STTK or ORMP?

In the previous week, Shattuck Labs had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 6 mentions for Shattuck Labs and 5 mentions for Oramed Pharmaceuticals. Shattuck Labs' average media sentiment score of 1.15 beat Oramed Pharmaceuticals' score of 0.01 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NVCT or ORMP?

Nuvectis Pharma presently has a consensus target price of $36.25, indicating a potential upside of 48.75%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Nuvectis Pharma is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NVCT or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% Oramed Pharmaceuticals N/A -5.17% -4.54%

Does the media refer more to NVCT or ORMP?

In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 5 articles in the media. Nuvectis Pharma's average media sentiment score of 0.78 beat Oramed Pharmaceuticals' score of 0.01 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ORMP or MNPR?

Monopar Therapeutics has a consensus price target of $118.67, indicating a potential upside of 0.10%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Monopar Therapeutics is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Monopar Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86

Is ORMP or MNPR more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Monopar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.17% -4.54% Monopar Therapeutics N/A -13.08% -12.79%

Does the media prefer ORMP or MNPR?

In the previous week, Oramed Pharmaceuticals had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 2 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.54 beat Oramed Pharmaceuticals' score of 0.01 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oramed Pharmaceuticals (ORMP) Competitors

$4.93 -0.14 (-2.76%)

As of 09/3/2026 04:00 PM Eastern

Compare

ORMP vs. SLN, NGNE, STTK, NVCT, and MNPR

Should you buy Oramed Pharmaceuticals stock or one of its competitors? Oramed Pharmaceuticals's main competitors and comparable companies include Silence Therapeutics (SLN), Neurogene (NGNE), Shattuck Labs (STTK), Nuvectis Pharma (NVCT), and Monopar Therapeutics (MNPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oramed Pharmaceuticals compare to Silence Therapeutics?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Oramed Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

In the previous week, Oramed Pharmaceuticals had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 2 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.70 beat Oramed Pharmaceuticals' score of 0.01 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silence Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Oramed Pharmaceuticals' return on equity of -5.17% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Oramed Pharmaceuticals has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	102.54	$64.05M	$4.12	1.20
Silence Therapeutics	$560K	1,590.19	-$88.61M	-$1.28	N/A

Silence Therapeutics has a consensus target price of $53.50, indicating a potential upside of 261.73%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Oramed Pharmaceuticals beats Silence Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Neurogene?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 11.7% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oramed Pharmaceuticals has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	102.54	$64.05M	$4.12	1.20
Neurogene	$930K	809.22	-$90.35M	-$5.03	N/A

Neurogene has a consensus target price of $83.67, suggesting a potential upside of 122.46%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 4 mentions for Neurogene. Neurogene's average media sentiment score of 1.48 beat Oramed Pharmaceuticals' score of 0.01 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurogene	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals' return on equity of -5.17% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Neurogene	N/A	-45.10%	-41.00%

Oramed Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

Summary

Oramed Pharmaceuticals and Neurogene tied by winning 8 of the 16 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Shattuck Labs had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 6 mentions for Shattuck Labs and 5 mentions for Oramed Pharmaceuticals. Shattuck Labs' average media sentiment score of 1.15 beat Oramed Pharmaceuticals' score of 0.01 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oramed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oramed Pharmaceuticals' return on equity of -5.17% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

Oramed Pharmaceuticals has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	698.51	-$48.81M	-$0.51	N/A
Oramed Pharmaceuticals	$2M	102.54	$64.05M	$4.12	1.20

Shattuck Labs has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Shattuck Labs presently has a consensus price target of $12.78, indicating a potential upside of 83.59%. Given Shattuck Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe Shattuck Labs is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Shattuck Labs and Oramed Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Nuvectis Pharma and Nuvectis Pharma both had 5 articles in the media. Nuvectis Pharma's average media sentiment score of 0.78 beat Oramed Pharmaceuticals' score of 0.01 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oramed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oramed Pharmaceuticals' return on equity of -5.17% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

Nuvectis Pharma has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Oramed Pharmaceuticals has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Oramed Pharmaceuticals	$2M	102.54	$64.05M	$4.12	1.20

Nuvectis Pharma presently has a consensus target price of $36.25, indicating a potential upside of 48.75%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Nuvectis Pharma is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Oramed Pharmaceuticals beats Nuvectis Pharma on 7 of the 13 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Monopar Therapeutics?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Oramed Pharmaceuticals had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 5 mentions for Oramed Pharmaceuticals and 2 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.54 beat Oramed Pharmaceuticals' score of 0.01 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Oramed Pharmaceuticals' return on equity of -5.17% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Monopar Therapeutics	N/A	-13.08%	-12.79%

Monopar Therapeutics has a consensus price target of $118.67, indicating a potential upside of 0.10%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Monopar Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Oramed Pharmaceuticals has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	102.54	$64.05M	$4.12	1.20
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A

Summary

Oramed Pharmaceuticals beats Monopar Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Oramed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORMP vs. The Competition

Export

Metric	Oramed Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$210.90M	$4.03B	$7.26B	$12.73B
Dividend Yield	4.93%	3.60%	2.53%	8.86%
P/E Ratio	1.20	12.66	273.28	25.38
Price / Sales	102.54	1,309.16	613.48	92.60
Price / Cash	55.88	106.87	77.82	52.26
Price / Book	0.65	16.29	12.89	6.14
Net Income	$64.05M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-1.99%	0.34%	0.61%	-0.27%
1 Month Performance	10.54%	8.52%	5.73%	0.68%
1 Year Performance	122.07%	52.66%	25.37%	14.84%

Oramed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORMP Oramed Pharmaceuticals	1.911 of 5 stars	$4.93 -2.8%	N/A	+124.1%	$210.90M	$2M	1.20	10	News Coverage Analyst Revision
SLN Silence Therapeutics	2.5515 of 5 stars	$13.67 +2.9%	$53.50 +291.4%	+195.2%	$800.18M	$560K	N/A	100
NGNE Neurogene	2.6243 of 5 stars	$40.84 +3.0%	$83.67 +104.9%	+89.3%	$793.25M	$930K	N/A	90	Positive News High Trading Volume
STTK Shattuck Labs	3.8252 of 5 stars	$8.06 +2.0%	$12.78 +58.5%	+443.8%	$792.87M	$1M	N/A	100	Positive News
NVCT Nuvectis Pharma	3.6604 of 5 stars	$25.89 +8.5%	$35.00 +35.2%	+283.8%	$779.21M	N/A	N/A	8	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORMP) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. SLN, NGNE, STTK, NVCT, and MNPR

How does Oramed Pharmaceuticals compare to Silence Therapeutics?

Summary

How does Oramed Pharmaceuticals compare to Neurogene?

Summary

How does Oramed Pharmaceuticals compare to Shattuck Labs?

Summary

How does Oramed Pharmaceuticals compare to Nuvectis Pharma?

Summary

How does Oramed Pharmaceuticals compare to Monopar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. SLN, NGNE, STTK, NVCT, and MNPR

How does Oramed Pharmaceuticals compare to Silence Therapeutics?

Which has more volatility & risk, ORMP or SLN?

Does the media prefer ORMP or SLN?

Is ORMP or SLN more profitable?

Which has higher valuation & earnings, ORMP or SLN?

Do analysts rate ORMP or SLN?

Do insiders & institutionals believe in ORMP or SLN?

Summary

How does Oramed Pharmaceuticals compare to Neurogene?

Do insiders and institutionals have more ownership in ORMP or NGNE?

Which has stronger earnings & valuation, ORMP or NGNE?

Do analysts rate ORMP or NGNE?

Does the media favor ORMP or NGNE?

Is ORMP or NGNE more profitable?

Which has more volatility and risk, ORMP or NGNE?

Summary

How does Oramed Pharmaceuticals compare to Shattuck Labs?

Do insiders & institutionals have more ownership in STTK or ORMP?

Does the media refer more to STTK or ORMP?

Is STTK or ORMP more profitable?

Which has preferable valuation & earnings, STTK or ORMP?

Which has more volatility & risk, STTK or ORMP?

Do analysts rate STTK or ORMP?

Summary

How does Oramed Pharmaceuticals compare to Nuvectis Pharma?

Do insiders and institutionals believe in NVCT or ORMP?

Does the media refer more to NVCT or ORMP?

Is NVCT or ORMP more profitable?

Which has more risk & volatility, NVCT or ORMP?

Which has stronger earnings & valuation, NVCT or ORMP?

Do analysts prefer NVCT or ORMP?

Summary

How does Oramed Pharmaceuticals compare to Monopar Therapeutics?

Do insiders & institutionals have more ownership in ORMP or MNPR?

Does the media prefer ORMP or MNPR?

Which has more risk and volatility, ORMP or MNPR?

Is ORMP or MNPR more profitable?

Do analysts prefer ORMP or MNPR?

Which has stronger earnings & valuation, ORMP or MNPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools